Resources Archive - Page 34 of 47

Discover our comprehensive platform of CDX and PDX tumor models, carrying BRAF mutations across multiple cancer types: 18 CDX models...

WuXi AppTec scientists recently contributed to a research study published in the journal Hepatology, characterizing the efficacy of prodrug DF-006...

Leverage our extensive panel of rat xenograft and syngeneic tumor models. Advantages for using rats in preclinical efficacy studies compared...

WuXi AppTec scientists recently contributed to a research article in the Journal of Medicinal Chemistry describing the optimization of a...

WuXi AppTec scientists recently contributed to a research article in the Royal Society of Chemistry describing the large-scale synthesis of...

Expansion of the E3 ligase toolbox has the potential to dramatically advance the field of targeted protein degradation. WuXi AppTec...

Delivery carriers are a critical component in the development of mRNA vaccines. Here, we describe the synthesis of a cationic...

KRAS mutant proteins that drive cancer development are highly similar in sequence and structure. Direct inhibitors are most likely to...

Expertise in all major disease areas and all major target classes, enabling discovery for all therapeutic modalities World class antiviral...

Knowledge Library